A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.

Authors

John Sarantopoulos

Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, San Antonio, TX

John Sarantopoulos , Muhammad Shaalan Beg , Georgios Fotopoulos , Josephine Amalia Taverna , Stephen P. Anthony , Steven D. Weitman , Steven L Warner , Lars Mouritsen , David Bearss , Susan Smith , Holly Beever , Vivek Khemka

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.

First Author: Jessica Dreger McDermott

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

First Author: Mark N. Stein

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.

First Author: Yong Sang Hong

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.

First Author: Sheng Li